Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) —…
Month: September 2023
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and…
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and…
PDS Biotech to Present at the LD Micro Main Event XVI
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech…
PDS Biotech to Present at the LD Micro Main Event XVI
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech…
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort…
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort…
Motus GI Submits Special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and Colon
– A special 510(k), according to FDA guidance, is usually reviewed within 30 days of…
Motus GI Submits Special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and Colon
– A special 510(k), according to FDA guidance, is usually reviewed within 30 days of…
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg…
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg…
AltruBio Announces FDA Clearance of IND Application for Immune Checkpoint Enhancer ALTB-268 to initiate a Phase 2 Clinical Trial for the Treatment of Ulcerative Colitis
Global multi-arm Phase 2 clinical trial expected to launch in 2024 SAN FRANCISCO, Sept. 26,…
AltruBio Announces FDA Clearance of IND Application for Immune Checkpoint Enhancer ALTB-268 to initiate a Phase 2 Clinical Trial for the Treatment of Ulcerative Colitis
Global multi-arm Phase 2 clinical trial expected to launch in 2024 SAN FRANCISCO, Sept. 26,…
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
Acasti Announces $7.5 Million Private Placement Equity Financing
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or…
FDA Accepts Defender Pharmaceuticals’ New Drug Application for Intranasal Scopolamine Gel
PDUFA date of January 26th, 2024 Assigned Priority Review Status at the Request of the…
Enable Announces Rebate Strategist Awards to Recognize its Customer Pioneers in Rebate Management
SAN FRANCISCO–(BUSINESS WIRE)–#AndrewButt—Enable, the leading rebate management platform, announced today its first-ever Rebate Strategist Awards…
Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism
– Topline clinical data anticipated in 1Q 2024 – – First-in-class small molecule therapeutic targets…
Ring Therapeutics Announces Two Late Breaker Presentations at the 30th Annual European Society of Gene & Cell Therapy Conference
Ring to present new data on its Anellogy™ platform The first new class of viral…
Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of RECCE® 327 for Urinary Tract Infections
Cohort dosing complete in healthy subjects, with the Phase I/II study on track to meet…